Literature DB >> 8922433

Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons.

R D Todd1, J Carl, S Harmon, K L O'Malley, J S Perlmutter.   

Abstract

Loss of nigrostriatal neurons leads to striatal dopamine deficiency and subsequent development of parkinsonism. The effects of this denervation on D2-like receptors in striatum remain unclear. Most studies have demonstrated increases in striatal dopamine D2-like receptors in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated denervation, but others have found either decreases or no change in binding. To clarify the response to denervation, we have investigated the time-dependent changes in dopamine D2, D3, and D4 receptor protein and mRNA levels in unilaterally MPTP-lesioned baboons. MPTP (0.4 mg/kg) was infused into one internal carotid artery, producing a contralateral hemi-parkinsonian syndrome. After MPTP treatment, the animals were maintained for 17-480 d and then euthanized. MPTP decreased ipsilateral dopamine content by >90%, which did not change with time. Ipsilateral D2-like receptor binding in caudate and putamen initially decreased then increased two- to sevenfold over the first 100 d and returned to near baseline levels by 480 d. Relative levels of D2 mRNA were essentially unchanged over this period. D4 mRNA was not detected. In contrast, D3 mRNA increased sixfold by 2 weeks and then decreased. At the peak period of increase in binding sites, all D2-like receptors were in a micromolar affinity agonist-binding state, implying an increase in uncoupled D2 but not D3 receptor protein. Taken together, these data suggest that MPTP-induced changes in D2-like dopamine receptors are complex and include translational or post-translational mechanisms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8922433      PMCID: PMC6579075     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  38 in total

1.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

2.  First-strand cDNA synthesis primed with oligo(dT).

Authors:  M S Krug; S L Berger
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

3.  Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys.

Authors:  P Falardeau; P J Bédard; T Di Paolo
Journal:  Neurosci Lett       Date:  1988-03-31       Impact factor: 3.046

4.  Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.

Authors:  H Bergman; T Wichmann; M R DeLong
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

5.  Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors.

Authors:  C M O'Hara; A Uhland-Smith; K L O'Malley; R D Todd
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030

6.  Dopamine D2 and D3 receptors inhibit dopamine release.

Authors:  L Tang; R D Todd; K L O'Malley
Journal:  J Pharmacol Exp Ther       Date:  1994-08       Impact factor: 4.030

7.  Lesions of mouse striatum induced by 6-hydroxydopamine differentially alter the density, rate of synthesis, and level of gene expression of D1 and D2 dopamine receptors.

Authors:  Z H Qin; J F Chen; B Weiss
Journal:  J Neurochem       Date:  1994-02       Impact factor: 5.372

8.  Pharmacological effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine receptor system.

Authors:  Y S Lau; Y K Fung
Journal:  Brain Res       Date:  1986-03-26       Impact factor: 3.252

9.  Non-steady-state measurement of in vivo radioligand binding with positron emission tomography: specificity analysis and comparison with in vitro binding.

Authors:  J S Perlmutter; S M Moerlein; D R Hwang; R D Todd
Journal:  J Neurosci       Date:  1991-05       Impact factor: 6.167

10.  Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists.

Authors:  C Gagnon; P J Bédard; T Di Paolo
Journal:  Eur J Pharmacol       Date:  1990-03-13       Impact factor: 4.432

View more
  18 in total

Review 1.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

Review 2.  Mutational and biochemical analysis of dopamine in dystonia: evidence for decreased dopamine D2 receptor inhibition.

Authors:  R D Todd; J S Perlmutter
Journal:  Mol Neurobiol       Date:  1998-04       Impact factor: 5.590

3.  Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.

Authors:  Maryka Quik; Li Chen; Neeraja Parameswaran; Xinmin Xie; J William Langston; Sarah E McCallum
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

4.  Regulation of dopamine presynaptic markers and receptors in the striatum of DJ-1 and Pink1 knockout rats.

Authors:  Jianjun Sun; Evguenia Kouranova; Xiaoxia Cui; Robert H Mach; Jinbin Xu
Journal:  Neurosci Lett       Date:  2013-10-22       Impact factor: 3.046

5.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

Review 6.  Task-specific dystonias: a review.

Authors:  Diego Torres-Russotto; Joel S Perlmutter
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

7.  Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.

Authors:  Fernando Caravaggio; Lawrence S Kegeles; Alan A Wilson; Gary Remington; Carol Borlido; David C Mamo; Ariel Graff-Guerrero
Journal:  Synapse       Date:  2016-07-11       Impact factor: 2.562

Review 8.  Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

Authors:  Agnès Nadjar; Charles R Gerfen; Erwan Bezard
Journal:  Prog Neurobiol       Date:  2008-09-30       Impact factor: 11.685

Review 9.  Research priorities in spasmodic dysphonia.

Authors:  Christy L Ludlow; Charles H Adler; Gerald S Berke; Steven A Bielamowicz; Andrew Blitzer; Susan B Bressman; Mark Hallett; H A Jinnah; Uwe Juergens; Sandra B Martin; Joel S Perlmutter; Christine Sapienza; Andrew Singleton; Caroline M Tanner; Gayle E Woodson
Journal:  Otolaryngol Head Neck Surg       Date:  2008-10       Impact factor: 3.497

10.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.